BeiGene(BGNE) - 2025 Q3 - Quarterly Results

Exhibit 99.1 BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates • Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 • Global BRUKINSA (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 ® • Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 • 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting Exhibit 99.1 Third Quarter 2025 Fina ...